Nuvation Bio NUVB Cash And Cash Equivalents And Marketable Securities
Cash And Cash Equivalents And Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept nuvb:CashAndCashEquivalentsAndMarketableSecurities.
The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvation Bio's cash and cash equivalents and marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvation Bio's cash and cash equivalents and marketable securities?
- Nuvation Bio (NUVB) reported cash and cash equivalents and marketable securities of $529.2M in Q4 2025.
- How has Nuvation Bio's cash and cash equivalents and marketable securities changed year-over-year?
- Nuvation Bio's cash and cash equivalents and marketable securities increased by 5.3% year-over-year, from $502.7M to $529.2M.
- What is the long-term trend for Nuvation Bio's cash and cash equivalents and marketable securities?
- Over 4 years (2021 to 2025), Nuvation Bio's cash and cash equivalents and marketable securities has grown at a -8.8% compound annual growth rate (CAGR), from $765.4M to $529.2M.
- What does cash and cash equivalents and marketable securities mean?
- This represents the total pool of highly liquid assets, including cash, bank deposits, and short-term investments that can be readily converted into cash. It is the primary measure of a company's immediate financial health and its ability to fund ongoing operations and research activities. Investors use this to calculate the company's cash runway and overall liquidity position.